Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkina Faso.

[1]  O. Müller,et al.  The Great Failure of Malaria Control in Africa: A District Perspective from Burkina Faso , 2007, PLoS medicine.

[2]  J. Le bras,et al.  Invasion of Africa by a single pfcrt allele of South East Asian type , 2006, Malaria Journal.

[3]  F. Mockenhaupt,et al.  Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86 , 2005, Annals of tropical medicine and parasitology.

[4]  F. Nosten,et al.  A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand , 2005, Malaria Journal.

[5]  O. Müller,et al.  Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841] , 2005, Malaria Journal.

[6]  J. May,et al.  High Prevalence of Markers for Sulfadoxine and Pyrimethamine Resistance in Plasmodium falciparum in the Absence of Drug Pressure in the Ashanti Region of Ghana , 2005, Antimicrobial Agents and Chemotherapy.

[7]  B. Coulibaly,et al.  Association of Plasmodium falciparum isolates encoding the p. Falciparum chloroquine resistance transporter gene K76T polymorphism with anemia and splenomegaly, but not with multiple infections. , 2005, The American journal of tropical medicine and hygiene.

[8]  O. Müller,et al.  Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso , 2005, Tropical medicine & international health : TM & IH.

[9]  O. Razum,et al.  Community effectiveness of chloroquine and traditional remedies in the treatment of young children with falciparum malaria in rural Burkina Faso , 2004, Malaria Journal.

[10]  O. Müller,et al.  Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria , 2004, European Journal of Clinical Pharmacology.

[11]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[12]  U. d’Alessandro,et al.  History, Dynamics, and Public Health Importance of Malaria Parasite Resistance , 2004, Clinical Microbiology Reviews.

[13]  S. Sirima,et al.  Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: a double-blind, randomized, controlled trial. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  O. Müller,et al.  Malaria morbidity, treatment‐seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso , 2003, Tropical medicine & international health : TM & IH.

[15]  O. Müller,et al.  Clinical efficacy of chloroquine in young children with uncomplicated falciparum malaria – a community‐based study in rural Burkina Faso , 2003, Tropical medicine & international health : TM & IH.

[16]  E. van Marck,et al.  Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000 , 2002, Tropical medicine & international health : TM & IH.

[17]  L. Ranford-Cartwright,et al.  Detection of mutations in the Plasmodium falciparum dihydrofolate reductase (dhfr) gene by dot-blot hybridization. , 2002, The American journal of tropical medicine and hygiene.

[18]  X. Su,et al.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[19]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[20]  J. May,et al.  Short report: high prevalence and imbalanced age distribution of the Plasmodium falciparum dihydrofolate reductase gene Asn108 mutation in an area of low pyrimethamine usage in Nigeria. , 1999, The American journal of tropical medicine and hygiene.

[21]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[22]  O. Doumbo,et al.  Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. , 1996, The American journal of tropical medicine and hygiene.

[23]  J. Ouédraogo,et al.  Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991). , 1994, The American journal of tropical medicine and hygiene.

[24]  H. Ginsburg,et al.  Identification of the acidic compartment of Plasmodium falciparum‐infected human erythrocytes as the target of the antimalarial drug chloroquine. , 1984, The EMBO journal.

[25]  T. Shapiro,et al.  Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge. , 2005, Annual review of pharmacology and toxicology.

[26]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[27]  J. Trape.  The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.